WO2012125832A3 - Antimicrobial agents - Google Patents

Antimicrobial agents Download PDF

Info

Publication number
WO2012125832A3
WO2012125832A3 PCT/US2012/029234 US2012029234W WO2012125832A3 WO 2012125832 A3 WO2012125832 A3 WO 2012125832A3 US 2012029234 W US2012029234 W US 2012029234W WO 2012125832 A3 WO2012125832 A3 WO 2012125832A3
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial agents
relates
agents
infective
proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/029234
Other languages
French (fr)
Other versions
WO2012125832A2 (en
Inventor
Erin M. Duffy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Priority to CA2829993A priority Critical patent/CA2829993A1/en
Priority to EP12756938.2A priority patent/EP2686308A2/en
Priority to PH1/2013/501882A priority patent/PH12013501882A1/en
Priority to AU2012229127A priority patent/AU2012229127A1/en
Priority to BR112013023536A priority patent/BR112013023536A2/en
Priority to SG2013068630A priority patent/SG193424A1/en
Publication of WO2012125832A2 publication Critical patent/WO2012125832A2/en
Publication of WO2012125832A3 publication Critical patent/WO2012125832A3/en
Priority to IL228388A priority patent/IL228388A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to substituted aromatic compounds useful as therapeutic agents.
PCT/US2012/029234 2011-03-15 2012-03-15 Antimicrobial agents Ceased WO2012125832A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2829993A CA2829993A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
EP12756938.2A EP2686308A2 (en) 2011-03-15 2012-03-15 Antimicrobial agents
PH1/2013/501882A PH12013501882A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
AU2012229127A AU2012229127A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
BR112013023536A BR112013023536A2 (en) 2011-03-15 2012-03-15 antimicrobial agents
SG2013068630A SG193424A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
IL228388A IL228388A0 (en) 2011-03-15 2013-09-12 Antimicrobial agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452884P 2011-03-15 2011-03-15
US61/452,884 2011-03-15

Publications (2)

Publication Number Publication Date
WO2012125832A2 WO2012125832A2 (en) 2012-09-20
WO2012125832A3 true WO2012125832A3 (en) 2012-11-08

Family

ID=46831352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029234 Ceased WO2012125832A2 (en) 2011-03-15 2012-03-15 Antimicrobial agents

Country Status (8)

Country Link
EP (1) EP2686308A2 (en)
AU (1) AU2012229127A1 (en)
BR (1) BR112013023536A2 (en)
CA (1) CA2829993A1 (en)
IL (1) IL228388A0 (en)
PH (1) PH12013501882A1 (en)
SG (1) SG193424A1 (en)
WO (1) WO2012125832A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1976828T (en) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
EP2768798A1 (en) 2011-10-17 2014-08-27 Zoetis LLC Novel phenicol antibacterials
UA110436C2 (en) 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
AU2013324198C1 (en) * 2012-09-26 2017-08-10 Zoetis Services Llc Phenicol antibacterial agents
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022864A8 (en) 2013-03-14 2019-11-26 Celtaxsys Inc compound, pharmaceutical composition and use thereof
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
PT2986592T (en) * 2013-04-17 2018-04-19 Zoetis Services Llc Novel phenicol antibacterial agents
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
KR20160070066A (en) 2013-09-09 2016-06-17 멜린타 테라퓨틱스, 인크. Antimicrobial compunds and methods of making and using the same
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
CN106631872A (en) * 2016-12-13 2017-05-10 浙江普洛家园药业有限公司 Synthesis method of florfenicol analogue intermediate
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
IL289445B2 (en) 2019-06-25 2025-03-01 Amtixbio Co Ltd A novel aminoalkanoic acid derivative containing a biphenyl group and an antifungal pharmaceutical composition comprising the same
CN115745823B (en) * 2022-11-03 2024-02-23 武夷学院 Preparation method and application of compound
CN115806501B (en) * 2022-12-13 2025-01-07 中国药科大学 N-oxalyl-D-phenylalanine compounds and ester prodrugs thereof, preparation method, pharmaceutical composition and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US5567844A (en) * 1984-02-03 1996-10-22 Zambon S.P.A. Process for preparing 1-phenyl-2-amino-3-fluoro-1-propanols
US20060014743A1 (en) * 2002-03-08 2006-01-19 Schering-Plough Animal Health Corporation Methods of preventing bacterial infections with florfenicol-type antibiotics
WO2008143729A2 (en) * 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US5567844A (en) * 1984-02-03 1996-10-22 Zambon S.P.A. Process for preparing 1-phenyl-2-amino-3-fluoro-1-propanols
US20060014743A1 (en) * 2002-03-08 2006-01-19 Schering-Plough Animal Health Corporation Methods of preventing bacterial infections with florfenicol-type antibiotics
WO2008143729A2 (en) * 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same

Also Published As

Publication number Publication date
WO2012125832A2 (en) 2012-09-20
BR112013023536A2 (en) 2016-12-06
AU2012229127A1 (en) 2013-10-03
CA2829993A1 (en) 2012-09-20
PH12013501882A1 (en) 2013-10-14
EP2686308A2 (en) 2014-01-22
IL228388A0 (en) 2013-12-31
SG193424A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
WO2012125832A3 (en) Antimicrobial agents
ZA202002470B (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP2875029B8 (en) 5,5-heteroaromatic anti-infective compounds
CO6811873A2 (en) Parasiticidal Dihydroisoxazole Compound
HUE037329T2 (en) Synergistic antimicrobial effect
ZA201305193B (en) Antimicrobial composition
PH12013501654A1 (en) Pesticidal compositions and processes related thereto
EP2723396A4 (en) Alkylaminoalkyl oligomers as broad-spectrum antimicrobial agent
IL229148A0 (en) Coating compositions comprising 2,2'-biphenol
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
BR112014013609A2 (en) solid antimicrobial composition, surface disinfection method and use of a composition
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
HK1201067A1 (en) Sialic acid analogs
WO2012170720A3 (en) Methods and compositions for treating brain cancer
WO2012170573A3 (en) New taccalonolide microtubule stabilizers
EP2672952A1 (en) Hair treatment compositions
EP3037091A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
ZA201307018B (en) Antimicrobial composition
EP3064203A4 (en) Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog as effective component
WO2012061165A3 (en) Methods and compositions for improving admet properties
EP2866569B8 (en) Antimicrobial composition
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
GB201117072D0 (en) Use of non e.164 msisdns
HUP1100597A2 (en) Primycin or its components or combination for the treatment or prevention of infestations by special organisms
ZA201403911B (en) Antimicrobial composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756938

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2829993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010462

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013558178

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012756938

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012229127

Country of ref document: AU

Date of ref document: 20120315

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201391311

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020137027125

Country of ref document: KR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013023536

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: JP

ENP Entry into the national phase

Ref document number: 112013023536

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130913